Poster présenté par Th. Farge (Inserm U1037) au meeting de l’AACR dédié aux modèles PDX (USA, New Orleans, 11-14 février 2016)
Poster presented by C. Pensec (Biofortis) at “PROBIOTA Congress” Amsterdam, “Onco Week” Toulouse and “4th R&D Business collaboration forum Europe” London
02/02/2016
Poster présenté par JF Mirjolet (Oncodesign) au congrès annuel de l’AACR (USA, New Orleans, 16-20 avril 2016)
16/04/2016
Studying cytarabine resistance through PDX models
in acute myeloid leukemia
in acute myeloid leukemia
Introduction
The major therapeutic barrier in acute myeloid leukemia (AML) is chemotherapy resistance. AML cells resistant to conventional chemotherapy targeting DNA synthesis are thought to be enriched in quiescent leukemic stem cells (LSCs). In order to better understand chemotherapy resistance in AML, we analyzed the response to cytarabine (AraC) through patient-derived xenograft (PDX) models with 20 primary AML patient specimens from two clinical sites and in the context of a French “Innovative models initiative” (IMODI) program.
Catégories
- Events (6)
- News (10)
- Newsletter (2)
- Poster (4)
Tags
Latest news
Discover and Share the Newsletter IMODI #2 – November 2016
14/11/2016
Oncomedics FOCUS: Personnalizing the cancer treatments
09/11/2016
Agreement for Oncodesign’s acquisition of GSK’s Research Centre
09/11/2016
2D/3D EX vivo Assays: A PDX-based platform for ex vivo evaluating/screening of novel anti-cancer compounds
26/10/2016
Join ModulBio at the ESBB Vienna 2016, booth 45
13/09/2016